Literature DB >> 26991242

Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery.

Travis T Wager1, Xinjun Hou1, Patrick R Verhoest1, Anabella Villalobos1.   

Abstract

Significant progress has been made in prospectively designing molecules using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the analysis reported herein of a second wave of drug candidates that originated after the development and implementation of this tool. This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochemical properties. The CNS MPO tool has helped to increase the percentage of compounds nominated for clinical development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA). The use of this tool has played a role in reducing the number of compounds submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicology into First in Human studies. Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compounds nominated for clinical development.

Entities:  

Keywords:  Attrition; CNS MPO; CNS candidates; CNS drug design; CNS drugs; Harrington optimization; Madin−Darby canine kidney; P-glycoprotein (P-gp); central nervous system (CNS); desirability score; efficacious drug concentration (Ceff); human liver microsome stability; hydrogen-bond donor; lipophilicity; molecular weight; most basic pKa; multiparameter optimization (MPO); multivariant optimization; passive permeability; polarity; topological polar surface area; unbound intrinsic clearance

Mesh:

Substances:

Year:  2016        PMID: 26991242     DOI: 10.1021/acschemneuro.6b00029

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  85 in total

1.  Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.

Authors:  Alan P Kozikowski; Sida Shen; Marta Pardo; Maurício T Tavares; Dora Szarics; Veronick Benoy; Chad A Zimprich; Zsófia Kutil; Guiping Zhang; Cyril Bařinka; Matthew B Robers; Ludo Van Den Bosch; James H Eubanks; Richard S Jope
Journal:  ACS Chem Neurosci       Date:  2018-12-14       Impact factor: 4.418

Review 2.  Small molecule targeting of RNA structures in neurological disorders.

Authors:  Alicia J Angelbello; Jonathan L Chen; Matthew D Disney
Journal:  Ann N Y Acad Sci       Date:  2019-04-09       Impact factor: 5.691

3.  A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity.

Authors:  Jerri M Rook; Jeanette L Bertron; Hyekyung P Cho; Pedro M Garcia-Barrantes; Sean P Moran; James T Maksymetz; Kellie D Nance; Jonathan W Dickerson; Daniel H Remke; Sichen Chang; Joel M Harp; Anna L Blobaum; Colleen M Niswender; Carrie K Jones; Shaun R Stauffer; P Jeffrey Conn; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2018-05-08       Impact factor: 4.418

4.  Discovery of 4-Piperazine Isoquinoline Derivatives as Potent and Brain-Permeable Tau Prion Inhibitors with CDK8 Activity.

Authors:  Jean-Marc M Grandjean; Alexander Y Jiu; John W West; Atsushi Aoyagi; Daniel G Droege; Manuel Elepano; Makoto Hirasawa; Masakazu Hirouchi; Ryo Murakami; Joanne Lee; Koji Sasaki; Shimpei Hirano; Takao Ohyama; Benjamin C Tang; Roy J Vaz; Masahiro Inoue; Steven H Olson; Stanley B Prusiner; Jay Conrad; Nick A Paras
Journal:  ACS Med Chem Lett       Date:  2020-01-30       Impact factor: 4.345

5.  Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([18F]N2B-0518) for GluN2B Subunit in the Brain.

Authors:  Hualong Fu; Weiting Tang; Zhen Chen; Vasily V Belov; Genwei Zhang; Tuo Shao; Xiaofei Zhang; Qingzhen Yu; Jian Rong; Xiaoyun Deng; Wei Han; Scott J Myers; Pilar Giffenig; Lu Wang; Lee Josephson; Yihan Shao; April T Davenport; James B Daunais; Mikhail Papisov; Hongjie Yuan; Zijing Li; Stephen F Traynelis; Steven H Liang
Journal:  ACS Chem Neurosci       Date:  2019-02-27       Impact factor: 4.418

6.  Novel M4 positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands.

Authors:  Michael S Poslusney; James M Salovich; Michael R Wood; Bruce J Melancon; Katrina A Bollinger; Vincent B Luscombe; Alice L Rodriguez; Darren W Engers; Thomas M Bridges; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2018-12-18       Impact factor: 2.823

Review 7.  Advances in Drug Discovery and Development in Geriatric Psychiatry.

Authors:  Alexander C Conley; Paul A Newhouse
Journal:  Curr Psychiatry Rep       Date:  2018-03-05       Impact factor: 5.285

8.  Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core.

Authors:  Blake R Bewley; Paul K Spearing; Rebecca L Weiner; Vincent B Luscombe; Xiaoyan Zhan; Sichen Chang; Hyekyung P Cho; Alice L Rodriguez; Colleen M Niswender; P Jeffrey Conn; Thomas M Bridges; Darren W Engers; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-08-20       Impact factor: 2.823

9.  The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core.

Authors:  Jeanette L Bertron; Hyekyung P Cho; Pedro M Garcia-Barrantes; Joseph D Panarese; James M Salovich; Kellie D Nance; Darren W Engers; Jerri M Rook; Anna L Blobaum; Colleen M Niswender; Shaun R Stauffer; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2018-05-05       Impact factor: 2.823

10.  Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice.

Authors:  Minjee Kim; Janice K Laramy; Afroz S Mohammad; Surabhi Talele; James Fisher; Jann N Sarkaria; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2019-01-31       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.